drugset / Trial / NCT06084819

Summary

The purpose of this study is to compare the efficacy and safety of venetoclax combined with CACAG regimen with BAT regimen in the treatment of relapsed/refractory acute myeloid leukemia.

Timeline

Start
2023-08-01
Primary completion
2029-01-31
Completion
2030-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Aclacinomycin Unknown 20 mg
Subject Azacitidine Other / unclassified 75 mg/m2
Comparator Cladribine Small molecule 5 unknown
Subject Cytarabine Small molecule 75 mg/m2
Subject Cytarabine Small molecule 100 mg/m2
Subject Cytarabine Small molecule 150 mg/m2
Subject Cytarabine Small molecule 200 mg/m2
Subject Cytarabine Small molecule 1 g/kg
Subject Cytarabine Small molecule 2 g/kg
Comparator Daunorubicin Small molecule 45 mg/m2
Comparator Decitabine Small molecule 20 mg/m2
Comparator Etoposide Small molecule 100 mg/m2
Comparator Fludarabine Small molecule 30 mg/m2
Comparator HHT Unknown 2 mg/m2
Comparator Mitox Unknown 10 mg/m2
Subject Tucidinostat Small molecule 30 mg
Subject Venetoclax Small molecule 400 mg
Background Granulocyte colony-stimulating factor Protein / enzyme biologic 300 ug